Management of Endometrial Abnormalities

Diagnostic Evaluation

The American College of Radiology recommends endometrial sampling for premenopausal women with abnormal bleeding, regardless of endometrial thickness, and considers sonohysterography to better evaluate the endometrial cavity 1
Transvaginal ultrasound (TVUS) is recommended as the first-line tool for measuring endometrial thickness, with the addition of color and spectral Doppler to improve assessment of endometrial vascularity, and combination with transabdominal ultrasound for anatomic overview, as recommended by the American College of Radiology 2, 1, 3
If ultrasound is inconclusive, consider sonohysterography or MRI pelvis without and with IV contrast, as recommended by the American College of Radiology 1
CT abdomen and pelvis with IV contrast is indicated if there is suspicion of malignancy, abnormal findings on ultrasound, or persistent unexplained bleeding, according to the American College of Radiology 3
MRI pelvis may be considered if ultrasound visualization is inadequate, and is superior for soft tissue characterization, according to the National Comprehensive Cancer Network 4

Patients with risk factors such as history of unopposed estrogen exposure, tamoxifen therapy, Lynch syndrome, obesity, diabetes mellitus, hypertension, and family history of gynecologic malignancy may require individualized management, despite thin endometrium 1
Patients with a history of unopposed estrogen exposure, tamoxifen therapy, Lynch syndrome, obesity, diabetes mellitus, hypertension, or family history of gynecologic malignancy may require individual assessment and consideration for endometrial sampling, despite an endometrial thickness ≤4mm 1
Patients with Lynch syndrome (particularly MLH1 gene) have increased risk of endometrial and ovarian cancer, and should consider hysterectomy with bilateral salpingo-oophorectomy starting at age 40, as recommended by the National Comprehensive Cancer Network 5

An endometrial thickness >11mm carries a significant risk of cancer, with a reported risk of approximately 6.7%, and urgent evaluation is needed, as recommended by the American College of Radiology 2
An endometrial thickness ≤4mm has a negative predictive value for endometrial cancer of nearly 100%, and no further evaluation is needed, as supported by the American College of Radiology and the American College of Obstetricians and Gynecologists 1, 6
Vaginal bleeding is the presenting symptom in >90% of endometrial cancer cases, so any bleeding in postmenopausal women requires immediate evaluation regardless of endometrial thickness 7, 6
Follow-up visit within 1-2 weeks is recommended if bleeding persists, and urgent evaluation if heavy bleeding, severe pain, or fever develops, to rule out complications or underlying pathology, as recommended by the American College of Obstetricians and Gynecologists 8

Combined estrogen-progestin regimens have a lower risk of endometrial cancer (RR, 0.4; 95% CI, 0.2 to 0.6) compared to non-users, as recommended by the American College of Obstetricians and Gynecologists and the European Society of Radiology 9, 10
Cyclic progestogens can revert hyperplasia to normal endometrium, although specific treatment details and efficacy rates are not cited here
Local estrogen therapy may be considered if not contraindicated, although specific administration guidelines are not provided here

The American College of Obstetricians and Gynecologists recommends NSAIDs for mild cramping and discomfort, as well as pelvic rest until bleeding resolves, for patients experiencing post-D&C spotting or bleeding 8
A thorough evaluation to rule out malignancy in post-hysterectomy patients with vaginal bleeding is recommended, including transvaginal ultrasound, vaginal cytology, targeted biopsies, and speculum examination, as recommended by the American College of Radiology 3
Patients with a history of CIN2/3 or cervical cancer should undergo vaginal cytology as part of their evaluation, according to the American Cancer Society 11